Back to search

Article

Reduced frequency dosing of osimertinib in EGFR-mutant non-small cell lung carcinoma: Real world data 

2023-12-20

Abstract excerpt

<h4>Introduction: </h4> Osimertinib has better efficacy than first generation EGFR-directed TKIs with similar safety profile. However, osimertinib is not affordable for most in developing nations. Moreover, minimum biologically effective dose of osimertinib may be less than approved, given uncertainty surrounding dose determination strategy for targeted agents Materials and Methods This was retrospective observati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
48cb7d04-7490-52a2-8ebd-3c8ac665cd0b
DOI
10.21203/rs.3.rs-3764071/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Reduced frequency dosing of osimertinib in EGFR-mutant non-small cell lung carcinoma: Real world dataDOI 10.21203/rs.3.rs-3764071/v1
Clinical Impact of Osimertinib Dose Reduction in the First-Line Setting on EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Monocentric StudySemantic proximity
Efficacy and safety of 40 mg osimertinib administered every other day for non-small cell lung cancer harboring an epidermal growth factor receptor mutation: A single-center retrospective cohort study.Semantic proximity
Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer.Semantic proximity
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.Semantic proximity
The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)Semantic proximity
Osimertinib in Advanced EGFR-T790M&nbsp;Mutation-positive Non-small Cell Lung Cancer Patients Treated Within the Special Use Medication Program in Spain. OSIREX-spanish Lung Cancer GroupSemantic proximity
Association Between Osimertinib Dose Reduction and Treatment Outcomes in First-Line EGFR-Mutated Advanced NSCLC: The Impact of Post-Progression Management.Semantic proximity
Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.Semantic proximity
First-line Osimertinib for Poor Performance Status Patients With EGFR Mutation-positive Non-small Cell Lung Cancer: A Prospective Observational StudySemantic proximity
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO).Semantic proximity
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).Semantic proximity
First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.Semantic proximity
Select a neighboring publication to make it the new centre.